These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 31173909)
21. Modified cells as potential ocular drug delivery systems. Tennikova T; Urtti A Drug Discov Today; 2019 Aug; 24(8):1621-1626. PubMed ID: 30562585 [TBL] [Abstract][Full Text] [Related]
22. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study. Singh J; Chhabra G; Pathak K Drug Dev Ind Pharm; 2014 Sep; 40(9):1223-32. PubMed ID: 23837522 [TBL] [Abstract][Full Text] [Related]
23. The gap between the need for novel retinal drug delivery methods, technologies in R&D phase, and approved ocular drug delivery technologies. Neumann R; Barequet D Drug Discov Today; 2019 Aug; 24(8):1433-1435. PubMed ID: 30904724 [TBL] [Abstract][Full Text] [Related]
24. Recent patents on ocular drug delivery systems. Conway BR Recent Pat Drug Deliv Formul; 2008; 2(1):1-8. PubMed ID: 19075892 [TBL] [Abstract][Full Text] [Related]
25. Poloxamer-based in situ gelling thermoresponsive systems for ocular drug delivery applications. Soliman KA; Ullah K; Shah A; Jones DS; Singh TRR Drug Discov Today; 2019 Aug; 24(8):1575-1586. PubMed ID: 31175956 [TBL] [Abstract][Full Text] [Related]
26. Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system. Geethalakshmi A; Karki R; Jha SK; Venkatesh DP; Nikunj B Curr Drug Deliv; 2012 Mar; 9(2):197-204. PubMed ID: 22283647 [TBL] [Abstract][Full Text] [Related]
27. Ocular delivery systems for topical application of anti-infective agents. Duxfield L; Sultana R; Wang R; Englebretsen V; Deo S; Rupenthal ID; Al-Kassas R Drug Dev Ind Pharm; 2016 Jan; 42(1):1-11. PubMed ID: 26325119 [TBL] [Abstract][Full Text] [Related]
28. Nanoparticles for drug delivery to the anterior segment of the eye. Janagam DR; Wu L; Lowe TL Adv Drug Deliv Rev; 2017 Dec; 122():31-64. PubMed ID: 28392306 [TBL] [Abstract][Full Text] [Related]
29. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Jiao J Adv Drug Deliv Rev; 2008 Dec; 60(15):1663-73. PubMed ID: 18845195 [TBL] [Abstract][Full Text] [Related]
30. Transport mechanism of chitosan-N-acetylcysteine, chitosan oligosaccharides or carboxymethyl chitosan decorated coumarin-6 loaded nanostructured lipid carriers across the rabbit ocular. Li J; Tan G; Cheng B; Liu D; Pan W Eur J Pharm Biopharm; 2017 Nov; 120():89-97. PubMed ID: 28867370 [TBL] [Abstract][Full Text] [Related]
31. [Advances in preservative-free glaucoma drops]. Stefan C; Pop A; Cojocaru I Oftalmologia; 2011; 55(2):3-6. PubMed ID: 21888063 [TBL] [Abstract][Full Text] [Related]
35. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye. Fangueiro JF; Veiga F; Silva AM; Souto EB Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225 [TBL] [Abstract][Full Text] [Related]
36. The ocular tolerability of a new ophthalmic drug delivery system (NODS). Diestelhorst M; Krieglstein GK Int Ophthalmol; 1994; 18(1):1-4. PubMed ID: 7960409 [TBL] [Abstract][Full Text] [Related]
37. Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Subrizi A; Del Amo EM; Korzhikov-Vlakh V; Tennikova T; Ruponen M; Urtti A Drug Discov Today; 2019 Aug; 24(8):1446-1457. PubMed ID: 30738982 [TBL] [Abstract][Full Text] [Related]
38. Experimental studies on soft contact lenses for controlled ocular delivery of pirfinedone: in vitro and in vivo. Yang M; Yang Y; Lei M; Ye C; Zhao C; Xu J; Wu K; Yu M Drug Deliv; 2016 Nov; 23(9):3538-3543. PubMed ID: 27331555 [TBL] [Abstract][Full Text] [Related]
39. Soft contact lenses for controlled ocular delivery: 50 years in the making. González-Chomón C; Concheiro A; Alvarez-Lorenzo C Ther Deliv; 2013 Sep; 4(9):1141-61. PubMed ID: 24024513 [TBL] [Abstract][Full Text] [Related]